LOX propeptide Antibody [FITC]

• Reactivity: Hu, Rt
• Applications: WB, Flow, ICC/IF, IP
• Clonality: Polyclonal
• Host: Rabbit
• Conjugate: FITC

LOX propeptide Antibody [FITC] Summary

• Immunogen: Synthetic peptide made to an internal portion of human LOX propeptide (within residues 118-168). [Swiss-Prot# P28300]
• Specificity: This antibody recognizes the glycosylated propeptide form (~35 kDa) and the proenzyme form (~50 kDa).
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: LOX
• Purity: Immunogen affinity purified

Applications/Dilutions

• Dilutions:
  • Flow Cytometry
  • Immunocytochemistry/ Immunofluorescence
  • Immunoprecipitation
  • Western Blot
• Application Notes: Optimal dilution of this antibody should be experimentally determined.

Packaging, Storage & Formulations

• Storage: Store at 4C in the dark.
• Buffer: PBS
• Preservative: 0.05% Sodium Azide
• Purity: Immunogen affinity purified

Notes

This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet.

Alternate Names for LOX propeptide Antibody [FITC]

• lysyl oxidaseEC 1.4.3.13
• MGC105112
• protein-lysine 6-oxidase

Background

Lysyl oxidase (LOX) is a critical enzyme in extracellular matrix biosynthesis as well as in the maintainance of normal bone phenotype. It is synthesized/secreted as a 50-kD proenzyme 'pro-LOX' which is then processed to 30-kD mature enzyme 'LOX' and 18-kD lysyl oxidase propeptide 'LOX-PP' by extracellular procollagen C-proteinases (BMP1, Tll1, and Tll2). LOX-PP has been proposed to implicate in the maintenance of inactive state of LOX within the secretory pathway and to act as intramolecular chaperones which facilitate the accurate protein folding/targeting to correct destinations. LOX-PP involves tumor suppression by inhibiting RAS-dependent cellular transformation and its expression has also been associated with inhibition of anchorage-independent progression as well as migration and growth suppression xenografts in Her-2/neu-driven breast cancer. LOX-PP also inhibits PI3K/AKT and ERK1/2 MAP kinase pathways, as well as the levels of downstream NF-kB/cyclin D1 signals in certain cancers - breast, pancreatic, lung, prostate and oral cancers. LOX-PP has also been shown to inhibit DNA synthesis in rat's VSMCs cultures, osteoblast proliferation and FGF-2 signaling.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: LOX